Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$19.36 +0.6%	$19.25	$15.47 ▼ $36.37	$662.36M	1.47	177,573 shs	136,991 shs
NWPHF Newron Pharmaceuticals	$9.36	$9.36	$9.10 ▼ $12.00	$167.08M	0.53	600 shs	N/A
PHAR Pharming Group	$9.43 +3.3%	$8.62	$6.65 ▼ $11.07	$641.60M	-0.08	6,553 shs	3,566 shs
TRVI Trevi Therapeutics	$6.50 +5.0%	$6.29	$2.30 ▼ $7.39	$649.30M	0.62	1.19 million shs	1.65 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	-3.05%	+6.73%	-27.22%	-0.72%
NWPHF Newron Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-22.00%
PHAR Pharming Group	0.00%	-5.97%	+17.59%	+3.29%	-1.66%
TRVI Trevi Therapeutics	0.00%	-1.52%	+7.08%	+59.71%	+135.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.0265 of 5 stars	3.6	0.0	0.0	0.0	2.0	0.0	0.0
NWPHF Newron Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	1.8549 of 5 stars	3.5	3.0	0.0	0.0	1.7	0.0	0.6
TRVI Trevi Therapeutics	3.6031 of 5 stars	4.7	2.0	0.0	0.0	3.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.17	Buy	$39.17	102.31% Upside
NWPHF Newron Pharmaceuticals	0.00	N/A	N/A	N/A
PHAR Pharming Group	3.00	Buy	$30.00	218.10% Upside
TRVI Trevi Therapeutics	3.30	Buy	$17.56	170.19% Upside

Current Analyst Ratings Breakdown

Latest NWPHF, AVBP, TRVI, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/20/2025	AVBP ArriVent BioPharma	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
3/20/2025	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$37.00 ➝ $37.00
3/19/2025	AVBP ArriVent BioPharma	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/19/2025	TRVI Trevi Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $20.00
3/19/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.50 ➝ $12.50
3/19/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
3/19/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $24.00
3/14/2025	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $39.00
3/14/2025	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$37.00 ➝ $37.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
NWPHF Newron Pharmaceuticals	$6.82M	24.50	N/A	N/A	$0.21 per share	44.57
PHAR Pharming Group	$320.71M	2.00	$0.10 per share	91.82	$3.26 per share	2.89
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	N/A
NWPHF Newron Pharmaceuticals	-$17.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	-$10.55M	-$0.20	N/A	314.37	N/A	-6.09%	-7.65%	-3.82%	7/30/2025 (Estimated)
TRVI Trevi Therapeutics	-$29.07M	-$0.45	N/A	N/A	N/A	N/A	-63.31%	-57.06%	N/A

Latest NWPHF, AVBP, TRVI, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/13/2025	Q4 2024	PHAR Pharming Group	$0.07	$0.05	-$0.02	$0.05	$76.67 million	$92.70 million
3/3/2025	Q4 2024	AVBP ArriVent BioPharma	-$0.78	-$0.60	+$0.18	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
NWPHF Newron Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
NWPHF Newron Pharmaceuticals	N/A	N/A	N/A
PHAR Pharming Group	0.41	3.53	2.76
TRVI Trevi Therapeutics	N/A	7.38	7.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
NWPHF Newron Pharmaceuticals	N/A
PHAR Pharming Group	0.03%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	N/A
NWPHF Newron Pharmaceuticals	N/A
PHAR Pharming Group	2.07%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
NWPHF Newron Pharmaceuticals	22	17.85 million	N/A	Not Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
TRVI Trevi Therapeutics	20	99.89 million	58.13 million	Optionable

NWPHF, AVBP, TRVI, and PHAR Headlines

Recent News About These Companies

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Increased by MPM Bioimpact LLC

May 16 at 8:38 AM | marketbeat.com

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 10, 2025 | marketbeat.com

Trevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finanznachrichten.de

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts

May 9, 2025 | marketbeat.com

Marshall Wace LLP Sells 38,203 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 8, 2025 | marketbeat.com

Ally Bridge Group NY LLC Lowers Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 4, 2025 | marketbeat.com

Acuta Capital Partners LLC Has $3.18 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 4, 2025 | marketbeat.com

Acorn Capital Advisors LLC Invests $8.24 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 4, 2025 | marketbeat.com

Boothbay Fund Management LLC Takes $387,000 Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 4, 2025 | marketbeat.com

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

May 1, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Here's Why

May 1, 2025 | marketbeat.com

Adage Capital Partners GP L.L.C. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 30, 2025 | marketbeat.com

JPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 30, 2025 | marketbeat.com

XTX Topco Ltd Makes New Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 28, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Silverarc Capital Management LLC

April 24, 2025 | marketbeat.com

Vivo Capital LLC Boosts Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 23, 2025 | marketbeat.com

Trevi Therapeutics management to meet virtually with B. Riley

April 22, 2025 | markets.businessinsider.com

Trevi Therapeutics management to meet with Cantor Fitzgerald

April 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWPHF, AVBP, TRVI, and PHAR Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$19.36 +0.12 (+0.62%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$19.37 +0.01 (+0.05%)

As of 05/16/2025 07:03 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Newron Pharmaceuticals OTCMKTS:NWPHF

$9.36 0.00 (0.00%)

As of 05/16/2025

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Pharming Group NASDAQ:PHAR

$9.43 +0.30 (+3.30%)

Closing price 05/16/2025 03:55 PM Eastern

Extended Trading

$9.43 0.00 (-0.01%)

As of 05/16/2025 04:05 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Trevi Therapeutics NASDAQ:TRVI

$6.50 +0.31 (+5.01%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$6.56 +0.06 (+0.86%)

As of 05/16/2025 07:44 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time